SCIE Stock Overview
SpectraScience, Inc. develops and markets a technology platform to instantly determine whether a tissue is normal, pre-cancerous, or cancerous without the need for a physical biopsy in the United States, Europe, and internationally.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
SpectraScience, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.000001 |
52 Week High | US$0.0001 |
52 Week Low | US$0.000001 |
Beta | 0 |
1 Month Change | 0% |
3 Month Change | 0% |
1 Year Change | -99.00% |
3 Year Change | -99.60% |
5 Year Change | 0% |
Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
SCIE | US Medical Equipment | US Market | |
---|---|---|---|
7D | 0% | 2.2% | 0.4% |
1Y | -99.0% | 13.3% | 28.8% |
Return vs Industry: SCIE underperformed the US Medical Equipment industry which returned 13.3% over the past year.
Return vs Market: SCIE underperformed the US Market which returned 28.8% over the past year.
Price Volatility
SCIE volatility | |
---|---|
SCIE Average Weekly Movement | n/a |
Medical Equipment Industry Average Movement | 7.7% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SCIE has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine SCIE's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1983 | n/a | Mike Oliver | https://www.spectrascience.com |
SpectraScience, Inc. develops and markets a technology platform to instantly determine whether a tissue is normal, pre-cancerous, or cancerous without the need for a physical biopsy in the United States, Europe, and internationally. It offers WavSTAT3 optical biopsy system to determine whether a colon tissue is normal, pre-cancerous, or cancerous without physically removing tissue from the body; and WavSTAT4 optical biopsy system, a colon diagnostic product that operates by using UV laser light to optically illuminate and analyze tissue, enabling the physician to make an instant diagnosis during endoscopy when screening for cancer. The company also sells mobile consoles and disposable forceps.
SpectraScience, Inc. Fundamentals Summary
SCIE fundamental statistics | |
---|---|
Market cap | US$4.97k |
Earnings (TTM) | -US$5.35m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs SCIE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
SCIE income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$196.44k |
Gross Profit | -US$196.44k |
Other Expenses | US$5.15m |
Earnings | -US$5.35m |
Last Reported Earnings
Sep 30, 2017
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did SCIE perform over the long term?
See historical performance and comparison